Profile

Elisabeth A. Tallant, Ph.D.Wake Forest School of Medicine

Elisabeth A. Tallant, Ph.D.

Assistant Director,
Professor,




Contact Information

Academic: 336-716-2108 | Department: 336-716-2108

Email: atallant@wakehealth.edu

Education & Training

  • B.S., University of Memphis, 1974
  • Ph.D., University of Tennessee-Memphis, 1983
  • Fellowship, University of Alabama-Birmingh, 1986

Memberships

  • Am Assn Of Advancement Of Scie
  • Am Assn for Cancer Research
  • Am Soc Biochem Molecular Bio
  • Am Heart Association
  • Am Physiological Society
  • Cons for SE Hypertension Contr
  • Council For High Blood Pressur
Elisabeth A. Tallant, Ph.D.

Elisabeth A. Tallant, Ph.D.

Assistant Director, Hypertension and Vascular Research Center
Professor, Hypertension
Comprehensive Cancer Center
Hypertension and Vascular Research Center
Cancer Biology
Physiology & Pharmacology

Research Interests

cancer/oncogenesis, cardiac function, cell growth, differentiation,d, drugs/therapeutic agents pharm, education/training (all f, t,, hormones/cytokines/signalling, hypertension, molecular biology/molecular me, prevention, vascular diseases, women's health issues

Contact Information

Academic: 336-716-2108 | Department: 336-716-2108

Email: atallant@wakehealth.edu

Recent Publications

Carver KA, Smith TL, Gallagher PE, Tallant EA. Angiotensin-(1-7) prevents angiotensin II-induced fibrosis in cremaster microvessels. Microcirculation. 2015;22(1):19-27.

Gallagher PE, Arter AL, Deng G, Tallant AE. Angiotensin-(1-7): a peptide hormone with anti-cancer activity. Curr Med Chem. 2014;21(21):2417-2423.

Bracey DN, Willey JS, Tallant EA, Gallagher PE, Wiggins WF, Callahan MF, Smith TL, Emory CL. The endogenous peptide angiotensin-(1-7) prevents radiation-induced muscle fibrosis: an in vivo murine model [abstract]. In: Proceedings of the 2014 Annual Meeting of the American Academy of Orthopaedic Surgeons; 2014 March 15-18; New Orleans (LA). 2014;():.

Krishnan B, Smith TL, Dubey P, Zapadka ME, Torti FM, Willingham MC, Tallant EA, Gallagher PE. Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis. Prostate. 2013;73(1):71-82.


Gallagher PE, Arter AL, Krishnan B, Garcia-Espinosa MA, Tallant EA. Angiotensin II/angiotensin-(1-7) In: Kastin AJ, ed. Handbook of biologically acive peptides. 2nd ed. Oxford: Academic Press;2013: 494-501.

Bracey D, Willey JS, Tallant EA, Gallagher PD [sic] [Gallagher PE], Smith TL, Callahan MF, Emory CL. The endogenous peptide angiotensin-(1-7) prevents radiation-induced muscle fibrosis: an in vivo murine model [abstract]. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S167.

Tallant EA, Howlett A, Grabenauer M, Thomas BF, Gallagher PE. The CB2 cannabinoid receptor mediates the anti-proliferative actions of angiotensin-(1-7) in vascular smooth muscle cells [abstract]. Hypertension. 2013;62(3 Suppl):465.

Bracey DN, Willey JS, Tallant EA, Gallagher PE, Smith TL, Callahan MF, Emory CL. Angiotensin-(1-7) prevents radiation-induced muscle fibosis: an in vivo murine model [abstract]. In: Proceedings of the 2013 Annual Meeting of the Southern Orthopedic Association; 2013 July 30-August 2; Palm Beach (FL). 2013;():.

Tallant EA, Howlett A, Grabenauer M, Thomas BF, Gallagher PE. The CB2cannabinoid receptor mediates the anti-proliferative actions of angiotensin-(1-7) in vascular smooth muscle cells [abstract]. In: Conference Program of the 2013 Carolina Cannabinoid Collaborative Conference; 2013 Oct 25-27; Richmond (VA). 2013;():.

Arter AL, Gallagher PE, Tallant EA. Angiotensin-(1-7) attenuates the proliferation of cancer-associated fibroblasts in triple negative breast cancer [abstract]. Cancer Res. 2013;73(3 Suppl):B34.

Arter A, Gallagher PE, Tallant AE [sic] [Tallant EA]. Angiotensin-(1-7) suppresses lung metastasis in the 4T1 orthotopic mammary carcinoma model [abstract]. In: Proceedings of the 2013 International Conference on Tumor Microenvironment and Cellular Stress; 2013 Sept 27-Oct 2; Corfu (Greece). 2013;():.

McCollum LT, Gallagher PE, Tallant EA. Angiotensin-(1-7) attenuates angiotensin II-induced cardiac remodeling associated with upregulation of dual-specificity phosphatase 1. Am J Physiol Heart Circ Physiol. 2012;302(3):H801-H810.

McCollum LT, Gallagher PE, Tallant EA. Angiotensin-(1-7) abrogates mitogen-stimulated proliferation of cardiac fibroblasts. Peptides. 2012;34(2):380-388.

Garcia-Espinosa MA, Lesser GJ, Debinski W, Tallant EA, Gallagher PE. Angiotensin-(1-7), a peptide hormone with therapeutic potential for the treatment of glioblastomas [abstract]. In: Proceedings of the 103rd Annual Meeting of the Amerian Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, Illinois. Philadelphia (PA): AACR. 2012;():Abstr 1938.

Arter AA, Metheny-Barlow L, Gallagher PE, Tallant EA. Angiotensin-(1-7) inhibits proliferative and fibrotic signaling mechanisms in triple negative breast cancer [abstract]. In: Proceedings of the 103rd Annual Meeting of the Amerian Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, Illinois. Philadelphia (PA): AACR. 2012;():Abstr 5224.

Nautiyal M, Katakam PV, Busija DW, Gallagher PE, Tallant EA, Chappell MC, Diz DI. Differences in oxidative stress status and expression of MKP-1 in dorsal medulla of transgenic rats with altered brain renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol. 2012;303(8):R799-806.

Carver KA, Smith TL, Gallagher PE, Tallant EA. Vascular remodeling by angiotensin peptide hormones alters reactivity of the microcirculation [abstract]. Hypertension. 2012;60(3 Suppl):530.

Tallant EA, Carver KA, Gallagher PE. Angiotensin-(1-7) attenuates PDGF-dependent migration of vascular smooth muscle cells [abstract]. Hypertension. 2012;60(3 Suppl):512.

Gallagher PE, Maglic D, Krishnan B, Castellino SM, Tallant EA. Angiotensin-(1-7) inhibits the growth of human pediatric rhabdomyosarcoma in a mouse xenograft model [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando (FL). Philadelphia (PA): AACR. 2011;():Abstr 5349.

Gallagher PE, Cook K, Soto-Pantoja D, Menon J, Tallant EA. Angiotensin peptides and lung cancer. Curr Cancer Drug Targets. 2011;11(4):394-404.

Diz DI, Arnold AC, Nautiyal M, Isa K, Shaltout HA, Tallant EA. Angiotensin peptides and central autonomic regulation. Curr Opin Pharmacol. 2011;11(2):131-137.

Carver KA, Smith TL, Gallagher PE, Tallant EA. Angiotensin-(1-7) attenuates angiotensin II-induced fibrosis through a reduction in connective tissue growth factor [abstract]. Hypertension. 2011;58(5):e178.

Tallant EA, Carver KA, Gallagher PE. Angiotensin-(1-7) reduces cardiac hypertrophy and fibrosis in mRen2.Lewis congenic rats [abstract]. Hypertension. 2011;58(5):e110.

Tallant EA, Holmes CH, Gallagher PE. Inhibition of cancer cell growth by muscadine grape seed and grape skin extracts [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, Florida. Philadelphia (PA): AACR. 2011;():Abstr 4220.

Gallagher PE, Tallant EA, Ferrario CM, inventors; Wake Forest University Health Sciences, assignee. Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth. United States patent US 8,034,781. 2011 Oct 11. 2011;():.

Varagic J, Ahmad S, Brosnihan KB, Groban L, Chappell MC, Tallant EA, Gallagher PE, Ferrario CM. Decreased cardiac Ang-(1-7) is associated with salt-induced cardiac remodeling and dysfunction. Ther Adv Cardiovasc Dis. 2010;4(1):17-25.

Nautiyal M, Tallant EA, Chappell MC, Diz DI. Mitogen-activated protein kinase phosphatase-1 (MKP-1) is low in dorsal medulla of hypertensive (mRen2)27 transgenic rats [abstract]. FASEB J. 2010;24(1 Meeting Abstracts):955.11.

Cook KL, Metheny-Barlow LJ, Tallant EA, Gallagher PE. Angiotensin-(1-7) reduces fibrosis in orthotopic breast tumors. Cancer Res. 2010;70(21):8319-8328.

Carver KA, Smith TL, Gallagher PE, Tallant EA. Angiotensin-(1-7) reduces angiotensin II-induced remodeling of the microcirculation [abstract]. Hypertension. 2010;56(5):e141-e142.

Nautiyal M, Katakam PV, Busija DW, Gallagher PE, Tallant EA, Chappell MC, Diz DI. Oxidative stress and low expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in dorsal medulla of hypertensive (mRen2)27 transgenic rats [abstract]. Hypertension. 2010;56(5):e156.

Cook KL, Soto PD, Gallagher P, Tallant EA. Angiotensin-(1-7) inhibition of human breast tumors with distinct hormone receptor expression results in a differential regulation of AKT [abstract]. Cancer Res. 2009;69(2 Suppl):240S.

Soto-Pantoja DR, Petty WJ, Gallagher PE, Tallant EA. Angiotensin-(1-7) inhibits triple negative tumor growth through the inhibition of angiogenesis and a reduction in placental growth factor PIGF [abstract]. Cancer Res. 2009;69(2 Suppl):103S.

Soto-Pantoja DR, Menon J, Gallagher PE, Tallant EA. Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Mol Cancer Ther. 2009;8(6):1676-1683.

Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM. Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin Cancer Res. 2009;15(23):7398-7404.

Gallagher PE, Tallant EA. Angiotensin-(1-7) reduces MAP kinase activity by upregulation of the dual-specificity phosphatase DUSP1 [abstract]. Hypertension. 2009;54(4):e35.

Tallant EA, McCollum LT, Gallagher PE. Angiotensin-(1-7) reduces Ang II-induced cardiac hypertrophy with an associated increase in the dual-specificity phosphatase 1 (DUSP1) [abstract]. Hypertension. 2009;54(4):e122.

Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM. Phase I study of angiotensin-(1-7), an endogenous antiangiogenic hormone: clinical, pharmacokinetic, and biomarker findings [abstract]. Mol Cancer Ther. 2009;8(12 Suppl 1):B208.

Lesser GJ, Carver KA, Newton SJ, Tallant EA, Gallagher PE. Angiotensin-(1-7), a small molecule inhibitor of glioblastoma growth [abstract]. J Clin Oncol. 2009;27(15 Suppl):2024.

Diz DI, Garcia-Espinosa MA, Gegick S, Tommasi EN, Ferrario CM, Tallant EA, Chappell MC, Gallagher PE. Injections of angiotensin-converting enzyme 2 inhibitor MLN4760 into nucleus tractus solitarii reduce baroreceptor reflex sensitivity for heart rate control in rats. Exp Physiol. 2008;93(5):694-700.

Menon J, Miller MS, Soto-Pantoja DR, Callahan MF, Tallant EA, Gallagher PE. Angiotensin-(1-7) reduces lung tumor incidence in a novel bitransgenic Ki-ras G12C mouse model of lung tumorigenesis through a reduction in cyclooxygenase-2 [abstract]. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008 Apr 12-16; San Diego, CA. Philadelphia (PA): AACR. 2008;():Abstr 4654.

Soto-Pantoja DR, Menon J, Gallagher PE, Tallant EA. Angiotensin-(1-7) inhibits the growth of human triple negative breast tumors in an orthotopic model [abstract]. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research ; 2008 Apr 12-16; San Diego (CA). Philadelphia (PA): AACR. 2008;():Abstr 2416.

Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM. Bi-directional translational research with angiotensin-(1-7) uncovers placental growth factor as a therapeutic target [abstract]. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research ; 2008 Apr 12-16; San Diego (CA). Philadelphia (PA): AACR. 2008;():Abstr 4968.

Tallant EA, Gallagher PE, Ferrario CM, inventors; Wake Forest University Health Sciences, assignee. Angiotensin (1-7) and angiotensin (1-7) agonists for inhibition of cancer cell growth. United States patent US 7,375,073. 2008 May 20. 2008;():.

Gallagher PE, Ferrario CM, Tallant EA. MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides. Am J Physiol Cell Physiol. 2008;295(5):C1169-1174.

Lesser G, Carver K, Newton S, Tallant EA, Gallagher P. Angiotensin-(1-7) inhibits the growth of human glioblastoma xenografts in nude mice [abstract]. Neuro Oncol. 2008;10(5):792.

Gallagher PE, Ferrario CM, Tallant EA. Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol. 2008;295(6):H2373-79.

Gallagher PE, Soto-Pantoja DR, Tallant EA. Angiotensin-(1-7) reduces endothelial cell growth and migration and increases VEGI to inhibit angiogenesis [abstract]. Hypertension. 2008;52(4):e72.

McCollum LT, Gallagher PE, Tallant EA. Angiotensin-(1-7) attenuates cardiac fibrosis and vascular hypertrophy in a model of angiotensin II-dependent hypertension [abstract]. Hypertension. 2008;52(4):e120.

Tallant EA, McCollum LT, Gallagher PE. Angiotensin-(1-7) increases DUSP-1 and reduces the endothelin-1-mediated increase in COX-2 and PGES-1 in cardiac fibroblasts [abstract]. Hypertension. 2008;52(4):e47-e48.

Trask AJ, Jessup JA, Tallant EA, Chappell MC, Ferrario CM. Renin-independent processing of angiotensin-(1-12) in the rat heart and isolated myocytes [abstract]. Hypertension. 2008;52(4):e45-e46.

Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM. Phase I trial of angiotensin-(1-7): an endogenous anti-angiogenic hormone [abstract]. J Clin Oncol. 2008;26(15 Suppl):634s.

Menon J, Soto-Pantoja DR, Callahan MF, Cline JM, Ferrario CM, Tallant EA, Gallagher PE. Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Res. 2007;67(6):2809-2815.

Gallagher PE, Soto-Pantoja DR, Tallant EA. Angiotensin-(1-7) inhibits angiogenesis by reducing endothelial cell growth [abstract]. Hypertension. 2007;50(4):e91.

Tallant EA, Gallagher PE. Angiotensin-(1-7) upregulates the mitogen-activated phosphatase DUSP1 in vascular smooth muscle cells [abstract]. Hypertension. 2007;50(4):e77.

Ferrario CM, Averill DB, Brosnihan KB, Chappell MC, Diz DI, Gallagher PE, Neves L, Tallant EA. Regulation of cardiovascular control mechanisms by angiotensin (1-7) and angiotensin-converting enzyme 2 In: Carey RM, ed. Hypertension and hormone mechanisms. Totowa (NJ): Humana Press;2007: 43-59.

Jessup JA, Gallagher PE, Averill DB, Brosnihan KB, Tallant EA, Chappell MC, Ferrario CM. Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Am J Physiol Heart Circ Physiol. 2006;291(5):H2166-2172.

Whaley-Connell AT, Chowdhury NA, Hayden MR, Stump CS, Habibi J, Wiedmeyer CE, Gallagher PE, Tallant EA, Cooper SA, Ferrario C, et al. Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Renal Physiol. 2006;291(6):F1308-1314.

Diz DI, Tommasi EN, Ferrario CM, Tallant EA, Gallagher PE. ACE2 inhibition in the nucleus of the solitary tract reduces baroreceptor reflex sensitivity [abstract]. Hypertension. 2006;48(4):e87.

Gallagher PE, Ferrario CM, Tallant EA. Molecular mechanisms for the regulation of angiotensin converting enzyme 2 by angiotensin peptides in vascular smooth muscle cells [abstract]. Hypertension. 2006;48(4):e72.

McCollum LT, Gallagher PE, Ferrario CM, Tallant EA. Angiotensin-(1-7) reduces COX-2 in cardiac fibroblasts [abstract]. Hypertension. 2006;48(4):e79.

Tallant EA, Ferrario CM, Gallagher PE. Cardioprotective role for angiotensin-(1-7) and angiotensin converting enzyme 2 in the heart. Future Cardiol. 2006;2(3):335-342.

Gallagher PE, Tallant EA, Ferrario CM. Angiotensin converting enzyme 2: a potential target for cardiovascular therapy In: Re RN, DiPette DJ, Schiffrin EL, Sowers JR, eds. Molecular mechanisms in hypertension. New York: Taylor & Francis;2006: 51-59.

Tallant EA, Menon J, Soto-Pantoja DR, Gallagher PE. Angiotensin peptides and cancer In: Kastin AJ, ed. Handbook of biologically active peptides. Boston: Academic Press;2006: 459-465.

Menon J, Tallant EA, Gallagher PE. Experimental and molecular therapeutics 17: novel therapeutic targets [abstract]. In: Proceedings of the 97th Annual Meeting of the American Association for Cancer Research ; 2006 Apr 1-5; Washington, DC. Philadelphia (PA): AACR. 2006;():Abstr 2160.

Soto-Pantoja DR, Gallagher PE, Tallant EA. Inhibition of angiogenesis by angiotensin-(1-7) [abstract]. In: Proceedings of the 97th Annual Meeting of the American Association for Cancer Research ; 2006 Apr 1-5; Washington, DC. Philadelphia (PA): AACR. 2006;():Abstr 950.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, Hypertension

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
USNWR 2013-2014Magnet Hospital RecognitionConsumer Choice2014 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.